Medicaid Drug Rebate Program (MDRP): States that participate in the MDRP are generally required to cover all FDA-approved medications from participating manufacturers, with certain exceptions
Clinical therapeutic effects and challenges of GLP-1 receptor agonists The primary GLP-1RAs used worldwide as anti-obesity drugs are liraglutide (Saxenda, Novo Nordisk) as a once-daily subcutaneous injection and semaglutide (Wegovy, Novo Nordisk) as a once-weekly subcutaneous injection
10.1056/NEJMoa2403347 [DOI] [PubMed] 64.Gragnano F, De Sio V, Calabr P (2024) FLOW trial stopped early due to evidence of renal protection with semaglutide
Metabolic benefits extend beyond weight loss, including improved insulin sensitivity, better lipid profiles, reduced inflammatory markers, and potential cardiovascular protection
Is behavior change really necessary if Im on a GLP-1